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Background. The human immunodeficiency virus type 1 (HIV-1) pandemic was ignited in Léopoldville (now known as Kin-
shasa), in the former Belgian Congo. Factors that jump-started its early expansion remain unclear. Nonlethal hepatitis C virus (HCV)
and human T-cell lymphotropic virus (HTLV-1) can be used to investigate past iatrogenic transmission.
Methods. We undertook a cross-sectional study of elderly inhabitants of Kinshasa, with serological assays, amplification, and
sequencing. Risk factors were assessed through logistic regression. Phylogenetic methods reconstructed the genetic history of HCV.
Results. A total of 217 of 839 participants (25.9%) were HCV seropositive; 26 (3.1%) were HTLV-1-seropositive. Amplification
products were obtained from 118 HCV-seropositive participants; subtypes 4k (in 47 participants) and 4r (in 38) were most common.
Independent risk factors for HCV subtype 4r seropositivity were intramuscular tuberculosis therapy, intravenous injections at hos-
pital A, intravenous injections before 1960, and injections at a colonial-era venereology clinic. Intravenous injections at hospital B
and antimalarials were associated with HCV subtype 4k seropositivity. Risk factors for HTLV-1 seropositivity included intravenous
injections at hospitals C or D and transfusions. Evolutionary analysis of viral sequences revealed independent exponential amplifi-
cation of HCV subtypes 4r and 4k from the 1950s onward.
Conclusions. Iatrogenic transmission of HCV and HTLV-1 occurred in mid-20th century Kinshasa, at the same time and place
HIV-1 emerged. Iatrogenic routes may have contributed to the early establishment of the pandemic.
Keywords. HCV; HTLV-1; HIV-1; Kinshasa; Democratic Republic of the Congo; iatrogenic transmission.
The human immunodeficiency virus (HIV)/AIDS pandemic
has affected approximately 75 million people, half of whom
have died [1]. The source of the pandemic strain, HIV-1
group M, is the Pan troglodytes troglodytes chimpanzee, which
inhabits central African forests west and north of the Congo
river [2, 3]. Cross-species transmission is thought to have oc-
curred through the manipulation of chimpanzee meat by hunt-
ers or cooks. The common ancestor of all group M infections
existed during the first 2 decades of the 20th century [4, 5].
After cross-species transmission, probably in southeastern
Cameroon, the virus appears to have travelled south, reaching
Léopoldville (now Kinshasa, Democratic Republic of the
Congo; DRC) by 1920 [4–6]. Evolutionary analyses of viral
gene sequences show that HIV-1 flourished and diversified in
the capital of the former Belgian Congo, which was the major
trading center of Central Africa [4, 5]. The virus spread to
Brazzaville, across the river, and to other cities of the Belgian
Congo from the mid-1930s and, later, to the rest of the world
[5]. This explains why the 2 oldest HIV-1 isolates, recovered
from a 1959 blood sample and a 1960 biopsy specimen, were
both procured in Kinshasa [4, 7] and why Kinshasa and Brazza-
ville harbor a very broad genetic diversity of HIV-1 [8, 9], as too
does rural Cameroon [6], where the ancestors of HIV-1 in apes
are located.
Genetic estimates of the transmission history of HIV-1 groupM
in central Africa indicate that the epidemic grew more slowly be-
fore 1950 and then transitioned to much faster exponential growth
sometime between 1952 and 1968 [4, 5]. Factors that drove the
emergence and spread of HIV-1 toward epidemic spread in
Kinshasa remain unknown. It has been hypothesized that iatro-
genic transmission routes contributed substantially to the early
dissemination of HIV-1 [10, 11]. Although risk factors for HIV-
1 transmission decades ago cannot be studied directly because of
its high mortality, 2 blood-borne viruses compatible with survival
can serve as proxies: hepatitis C virus (HCV) and human T-cell
lymphotropic virus type 1 (HTLV-1). HCV provides a valuable
marker for iatrogenic transmission as sexual and vertical routes
are comparatively less effective. To assess the contribution of
iatrogenic transmission to the spread of blood-borne viruses in
Kinshasa, we conducted a cross-sectional study of HCV and
HTLV-1 infections among the city’s elderly population.
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METHODS
Study Population and Data Collection
The protocol was approved by the ethics committees of École de
Santé Publique de Kinshasa and Centre Hospitalier Universi-
taire de Sherbrooke. The study was registered at ClinicalTrials.
gov, (NCT02439918). The unlinked anonymous method was
used. In July‒August 2012, we recruited a convenience sample
of individuals aged ≥70 years who had lived in Kinshasa for
≥30 years, understood Lingala, and were not demented or apha-
sic. Potential participants were identified through Catholic
parishes. Facilitators visited neighborhoods to explain to candi-
dates the purpose of the study and to seek their collaboration.
Those who gave a written consent in Lingala came to the parish,
where nurses administered a questionnaire and collected sam-
ples under medical supervision.
The questionnaire collected demographic data and past med-
ical history, focusing on tropical diseases and intravenous injec-
tions during the participant’s lifetime. Regions of birth were
categorized according to geographic proximity and/or common
ethnicity. For each episode of intravenous treatment, we sought
information concerning the indication, the approximate year,
and the healthcare facility. Timing was estimated by reference
to well-known historical events (Congo’s independence, in
1960; the nationalization of all foreign-owned enterprises, in
1973; and the Sovereign National Conference, in 1990–1992),
which were then used to define periods for analyses. We did
not attempt to document all injections received intramuscularly
or subcutaneously, as participants would have received too
many such injections. Instead, information was collected con-
cerning conditions that required an outstanding number of
injections (diabetes, streptomycin-treated tuberculosis, and
injectable contraceptives), transfusions, vaccine scars, scarifica-
tions, circumcision, and care received at a colonial-era venere-
ology clinic.
We expected an underlying prevalence of HCV of 15% in in-
dividuals unexposed to intravenous injections and a risk ratio of
1.6 between those exposed and those unexposed. The recruit-
ment target was thus set at 650 participants, which correspond-
ed to a power of 80% and a significance level of 5%. As the
recruitment phase proceeded faster than anticipated, the target
sample size was increased to 800. This improved the power of
the study to slightly <90%.
Laboratory Assays
Dried blood spots were made from capillary blood specimens
deposited on Whatman 3 filter paper (for serological analysis)
and Whatman Protein Saver Cards (for molecular biologic
analysis; Sigma-Aldrich). To document our 2 main outcomes
(HCV and HTLV-1 infections), serological assays were per-
formed as detailed in Supplementary Methods. For HCV,
polymerase chain reaction amplification of the NS5b (485 nu-
cleotides) and core/E1 (1026 nucleotides) genome regions was
attempted on reactive samples. For HTLV-1, the gp21 env gene
was amplified (885 nucleotides). Amplification and sequencing
are outlined in the Supplementary Methods. Sequences have ac-
cession numbers KP347272‒431.
Data Analysis
Classical Epidemiology
Crude and adjusted odds ratios (ORs) and their 95% confidence
intervals (CIs) were calculated by logistic regression. Models for
multivariable analyses were built starting with the variable most
strongly associated with the outcome in univariable analyses,
adding variables one by one until no other reached significance.
When the final model was reached, each variable was dropped
in turn, using likelihood ratio tests (significance level, 0.05) to
determine whether a given variable enhanced model fit. Wald
tests assessed stratum-specific significance for each categorical
variable. As the participants had been recruited through specific
parishes, parish was included, along with age, in all models to
allow for unmeasured confounders. Interaction tests were per-
formed only for variables, which, a priori, could have been re-
lated so as to generate effect modification.
HCV sequences were subtyped by computing p-distances to a
reference alignment of HCV subtype 4 isolates [12]. A distance
threshold of <0.15 was used to assign subtypes. Analyses for
specific HCV subtypes considered only participants infected
with that subtype and those who were seronegative; those infect-
ed with another subtype were considered refractory to the sub-
type of interest [13].
Evolutionary Epidemiology
In addition to the HCV sequences from this study, all other ge-
notype 4 gene sequences from the DRC that spanned the core or
NS5b regions sequenced here were collated from GenBank
(Supplementary Table 1). Sequences were aligned by hand,
and maximum likelihood phylogenies were estimated using
Garli 0.951 [14] from 4 alignments: (1) HCV subtype 4k core
sequences, (2) subtype 4k NS5b sequences, (3) subtype 4r
core sequences, and (4) subtype 4r NS5b sequences.
Evolutionary rates and epidemic histories were estimated
using the Bayesian phylogenetic approach with BEAST [15].
Both HCV subtypes prevalent here (4k and 4r) were analyzed
independently. Analyses were repeated, first using sequences
from this study only and second using those plus all other
HCV DRC sequences from GenBank. Evolutionary rates were
estimated from an independent set of HCV genotype 1 genomes
sampled from different patients at different times (Supplemen-
tary Methods) [16].
To ensure the robustness of results, a variety of coalescent
and molecular clock methods for estimating epidemic history
were used: both strict and relaxed molecular clock models
were tested, and parametric and nonparametric coalescent
models were explored [17, 18]. The parametric coalescent ap-
proach comprised a 3-phase model of epidemic history
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representing sequential phases of constant population size, ex-
ponential growth, and constant size (hereafter, the “CEC
model”) [19].
RESULTS
Classical Epidemiology
A total of 848 participants were enrolled. Nine did not fulfill the
inclusion criteria and were excluded despite blood specimens
having been collected. Thirty-five other potential participants
had been given a study number but were excluded before
blood specimen collection, as they were found to be ineligible
on the basis of age upon review of their identity papers by
one of the study physicians. Among the 839 eligible partici-
pants, ages varied between 70 and 97 years (median, 75 years;
interquartile range [IQR], 72–79 years). Participants had lived
in Kinshasa for 30–92 years (median, 58 years; IQR, 50–70
years). Seventy-four percent of participants recalled receiving
intravenous injections at least once in their lifetime.
Twenty-six percent of participants (217 of 839) were HCV
seropositive, while 1% (11) had an indeterminate HCV status.
Supplementary Table 2 shows the likelihood of HCV infection
according to various characteristics. In multivariable analysis
(Table 1), the independent risk factors for HCV infection
were intramuscular antituberculous injections, a first episode
of intravenous treatment prior to 1960, intravenous injections
at hospitals A or B, transfusions, and intravenous antimalarials.
No evidence of interaction was found. Injections at the colonial-
era venereology clinic (adjusted OR, 1.56; 95% CI, .96–2.53;
P = .07), injections against schistosomiasis (adjusted OR, 2.79;
95% CI, .93–8.32; P = .07), and a vaccinia scar (adjusted OR,
1.72; 95% CI, .99–3.02; P = .06) were weakly correlated with
HCV infection. Among men, having undergone medical cir-
cumcision was associated with HCV infection (adjusted OR,
1.98; 95% CI, 1.09–3.57; P = .02).
To allow, with sufficient numbers, stratification of exposures
according to the approximate year they occurred, periods were
further grouped as pre-1960, 1960–1973, and post-1973 (Sup-
plementary Table 3). HCV prevalence was higher for treatments
that occurred before 1960 or in the subsequent decade, with the
exception of injections at hospital A (inaugurated in 1958).
HCV subtypes were determined for 118 participants: 116 be-
longed to genotype 4, and 1 each to genotypes 1 and 7. The
most-common subtypes were 4k (n = 47), 4r (n = 38), and 4c
(n = 11). Supplementary Table 4 displays risk factors for sub-
types 4k and 4r. In multivariable modeling, intravenous antima-
larials and intravenous injections at hospital B were associated
with subtype 4k, while antituberculous injections, intravenous
injections at hospital A, injections at the colonial-era venereol-
ogy clinic, and a first episode of intravenous injections before
1960 were associated with subtype 4r (Table 2).
The prevalence of HTLV-1 infection was only 3.1% (26 of
839 participants). Five participants were excluded (2 were
Table 1. Independent Risk Factors for Hepatitis C Virus Seropositivity
Risk Factor Adjusted ORa (95% CI) P Value
Injections against tuberculosis
Never 1 .01
Ever 3.52 (1.32–9.40)
Intravenous injections at hospital B
Never 1 .05
Ever 2.69 (1.00–7.22)
First episode of intravenous injections
Before 1960 2.31 (1.35–3.97) .002
1960–1973 1.50 (.86–2.60) .15
1974–1992 1.44 (.89–2.33) .14
After 1992 1 .26
Never 1.34 (.81–2.21)
Intravenous injections at hospital A
Never 1 .05
Ever 1.83 (1.00–3.34)
Transfusions
Never 1 .02
Ever 1.65 (1.10–2.48)
Intravenous antimalarial drugs
Never 1 .04
Ever 1.50 (1.02–2.20)
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for the other variables in the model, as well as for age and parish of recruitment.
Table 2. Independent Risk Factors for Infection With Hepatitis C Virus
(HCV) Subtypes 4k and 4r
HCV Subtype, Risk Factor Adjusted ORa (95% CI) P Value
4k
Intravenous injections at hospital B
Never 1 .05
Ever 3.98 (1.01–15.75)
Intravenous antimalarial drugs
Never 1 .02
Ever 2.10 (1.13–3.90)
4r
Injections against tuberculosis
Never 1 <.001
Ever 12.80 (3.79–43.21)
Intravenous injections at hospital A
Never 1 .008
Ever 3.85 (1.43–10.41)
Injections at venereology clinic
Never 1 .03
Ever 2.60 (1.08–6.25)
First episode of intravenous injections
Before 1960 2.91 (1.03–8.26) .04
1960–1973 1.42 (.42–4.81) .57
1974–1992 1.84 (.70–4.80) .22
After 1992 1 .9
No intravenous injections 0.94 (.34–2.60)
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for the other variables in the model, as well as for age and parish of recruitment.
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infected with HTLV-2, and 3 were infected with an unknown
type or had an indeterminate HTLV status). The prevalence of
HTLV-1 infection according to various characteristics is shown
in Supplementary Table 5. Table 3 displays the independent
risk factors for HTLV-1 infection: female sex, birth in Equateur
or Orientale provinces, transfusions, and intravenous injections
at hospitals C or D. No evidence of interaction was found.
HTLV-1 sequences were available for 23 participants: 20 were
infected with subtype 1b, and 3 were infected with subtype 1a.
Subtype 1b isolates grouped in one of 2 clades, one containing
only DRC strains and the other containing isolates from Cam-
eroon and the Central African Republic (Supplementary Fig-
ure 1). Small numbers precluded comparisons of risk factors
for HTLV-1 infection by subtype.
HCV infection was more common in HTLV-1–infected par-
ticipants (12 of 26 [46.2%]) than among HTLV-1–uninfected
participants (204 of 797 [25.6%]; P = .03). When fitted into
the model for the other virus, HTLV-1 was a significant corre-
late of HCV infection, and HCV was a significant correlate of
HTLV-1 infection (data not shown).
Evolutionary Epidemiology
Supplementary Figures 2 and 3 show estimated maximum like-
lihood phylogenies for the HCV core and NS5b regions, and
Supplementary Figure 4 shows the maximum clade credibility
molecular clock trees for each data set. Figure 1 shows the re-
constructed epidemic histories of HCV subtypes 4r and 4k in
our study population (insufficient samples were available for
other subtypes). Both subtypes, both genome regions, and all
analysis methods produced congruent estimates of epidemic
growth trajectory. The common scenario was one of a low, en-
demic size until the mid-20th century, followed by a period of
rapid exponential growth. The growth phase was followed, in
most but not all cases, by a second phase of constant size near
the present. Owing to the low lineage coalescence rate near the
present, it is difficult to discern whether this plateau is due to sta-
bilized prevalence, longer times between infection, lack of statis-
tical power, or some combination of these factors. During the
epidemic phase, the effective number of infections increased be-
tween approximately 10-fold and approximately 100-fold. Addi-
tion of all other available DRC HCV sequences to the analysis
produced similar results (Supplementary Figure 5).
The CEC model was used to estimate the growth rate and the
start and end dates of the epidemic phase (Figure 2A). Estimates
of r, the exponential growth rate, were high for both subtypes
(corresponding to an epidemic doubling time of approximately
2–3 years) and similar to those previously reported for the Egyp-
tian HCV epidemic [18], the parenteral causes of which are well
characterized [19]. The average estimated start date of the growth
phase is 1956 (range, 1947‒1965; Figure 2B). Similar estimates
were obtained when all other known HCV DRC sequences
were included and when sequences from the 2 genome regions
were combined (average start date, 1955; Supplementary Figure 6).
The estimated end date of the growth phase was more variable
among data sets; on average, it was 1979 (range, 1967‒1992; Fig-
ure 2C). Growth phase start and end dates were typically earlier
for the core data sets, suggesting that the core region evolutionary
rate was marginally underestimated or that the NS5B rate was
overestimated.
DISCUSSION
During the colonial era in much of sub-Saharan Africa, poorly
effective antimicrobials were administered intravenously with
reused and inadequately sterilized syringes and needles, poten-
tially facilitating the transmission of blood-borne viruses, a risk
then unknown [10]. Previous epidemiological studies have sup-
ported the iatrogenic transmission, approximately 40 to approx-
imately 70 years ago, of 3 different blood-borne viruses: HIV-2,
in Guinea-Bissau (through treatment of African trypanosomia-
sis and tuberculosis); HCV, in Cameroon (through receipt of
antimalarials and transfusions), Egypt (through treatment of
schistosomiasis), and the Central African Republic (through
treatment of trypanosomiasis); and HTLV-1, in the Central Af-
rican Republic (through receipt of transfusions and chemopro-
phylaxis of trypanosomiasis) [13, 20–22].
The current study combined 2 independent sources of infor-
mation, classical epidemiology and viral gene sequences, to re-
construct the time scale and causes of past viral transmission in
Kinshasa. It revealed that, among elderly long-term residents of
Kinshasa, multiple risk factors from the 1950s onward drove
rapid iatrogenic transmission of HCV. HTLV-1 infection was
also associated with parenteral risk factors. Since Kinshasa is
Table 3. Independent Risk Factors for Human T-Cell Lymphotropic Virus
Type 1 Infection
Risk Factor Adjusted ORa (95% CI) P Value
Intravenous injections at hospital D
Never 1 .02
Ever 4.93 (1.37–17.69)
Sex
Male 1 .009
Female 4.45 (1.46–13.60)
Region of birth
Bas-Congo/Bandundu/Kinshasa 1 .005
Équateur/Orientale 3.49 (1.46–8.36) .9
Kasaï 1.09 (.29–4.19) . . .
Kivu/Katanga . . .
Transfusions
Never 1 .04
Ever 2.46 (1.04–5.85)
Intravenous injections at hospital C
Never 1 .05
Ever 2.41 (1.01–5.73)
Abbreviations: CI, confidence interval; OR, odds ratio.
a Adjusted for the other variables in the model, as well as for age and parish of recruitment.
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Figure 1. Reconstructed transmission history of hepatitis C virus (HCV) subtypes 4r and 4k in Kinshasa. Each plot shows the change through time in epidemic size (calculated
as [effective population size] × [generation time]) on a log scale. Thick lines indicate the median estimate and the shaded areas show the 95% highest posterior density credible
region. Estimates from both the HCV core region and the NS5B region are shown; see the key in the top right. A, Results for subtype 4r. B, Results for subtype 4k. For each
subtype, 4 different molecular clock and coalescent model combinations (1–4) are shown.
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the location where HIV-1 group M was established some 60
years ago and from where it was ultimately exported to the
rest of the world [5], it is plausible that the same factors were
involved in the simultaneous amplification of HIV-1.
The high genetic diversity of HCV genotype 4 isolates sup-
ports prior findings that it originated from central Africa [23].
Intravenous antimalarials were associated with genotype 4 in-
fection in Kinshasa, where many febrile illnesses are diagnosed
as malaria without supporting evidence and where healthcare
workers, often directly paid by patients, prefer to administer
an injectable, desired, and, hence, more lucrative treatment.
As was the case for HIV-2 in Bissau [21], HCV was transmitted
Figure 2. Estimated growth rate and time scale of hepatitis C virus (HCV) subtype 4r and 4k spread in Kinshasa. The CEC model (see “Methods” section) was used to
estimate 3 epidemic parameters for each data set: the exponential growth rate during the epidemic phase (A), the start date of the exponential phase (B), and the end date of
the exponential phase (C). Boxes and points indicate the median estimate for each parameter, while error bars show the 95% highest posterior density credible regions. Open
boxes and points represent values estimated using a strict molecular clock model; solid boxes and points represent those estimates using a relaxed molecular clock model.
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in Kinshasa during the treatment of tuberculosis with intramus-
cular streptomycin, used throughout the second half of the 20th
century [11]. While an intramuscular injection is less prone to
transmit HCV (or HIV) than an intravenous injection [24],
because a lower inoculum is not pushed directly into a vein,
patients with tuberculosis received 60–100 streptomycin injec-
tions, daily or twice weekly, and the risk was commensurate.
Specific HCV subtypes were associated with intravenous in-
jections, for any indication, in 2 Kinshasa hospitals, while
HTLV-1 positivity correlated with intravenous injections in 2
other hospitals, illustrating the importance of founder effects
generated by the introduction, or lack thereof, of a particular
viral strain within the patient population of a given facility. Fur-
ther, HCV subtype 4r infection was associated with injections at
a colonial-era venereology clinic where hundreds of intravenous
injections were performed each day, with syringes and needles
merely rinsed between patients, leading to an outbreak of so-
called inoculation hepatitis in 1951–1952 [12, 25, 26].
Albeit less prevalent than HCV, HTLV-1 is an interesting
proxy for historical transmission of HIV-1, as it shares a simian
reservoir and the capacity to infect CD4+ T cells [27]. Our re-
sults indicate that iatrogenic transmission facilitated the spread
of HTLV-1 in Kinshasa, along with sexual and vertical routes,
even if contaminated injections may be less prone to transmit
HTLV-1 because the virus is present as proviral DNA within
lymphocytes, not as free virions. Blood transfusions, which re-
main unscreened for viruses other than HIV, were administered
to one fifth of participants and allowed the transmission of
HTLV-1 and HCV, illustrating the co-occurrence in Kinshasa
of multiple modes of iatrogenic transmission of blood-borne vi-
ruses. The higher HTLV-1 prevalence among women is in line
with other studies and with more effective heterosexual trans-
mission from males to females than vice versa [27].
Although our evolutionary and epidemiological analyses
both have limitations, they are based on independent data (al-
beit from the same sample set) and on different model assump-
tions, and thus support each other. For some HCV-infected
participants who cleared the virus, antibody titers may have
waned below the cutoff for positivity [28]. Individuals who
died from cirrhosis or liver cancer were not available for
study, so, in theory, HCV subtypes perhaps less prone to
cause liver disease might be overrepresented. Individuals who
acquired HIV infection more than a decade ago, some of
them parenterally, were also likely absent from this population.
Incomplete recall of medical interventions is inevitable for
events that occurred decades earlier. These factors may have bi-
ased our measures of association.
Further, a low HTLV-1 prevalence limited our statistical
power for that retrovirus. It is likely that other modes of
iatrogenic transmission of blood-borne viruses operated in
Kinshasa, which we were unable to document with confidence.
This is suggested by the independent association between
HCV and HTLV-1 infections, which may reflect unmeasured
parenteral exposures common to both viruses (residual
confounding).
In cross-sectional studies such as ours, the time sequence be-
tween exposures and outcomes is unclear. However, evolution-
ary analyses of virus gene sequences from precisely the same
study population provided an independent estimate of when
HCV transmission took place. Although such analyses can be
susceptible to the presence of recombination or strong natural
selection in the viral population, recombination is uncommon
for HCV, and the congruence of results from different viral ge-
nome regions indicates that our results are robust to the effects
of selection.
Iatrogenic transmission can drive HCV to high prevalence
because, in contrast with HIV-1, most patients survive and re-
main viremic for decades, and the per-exposure efficacy of its
parenteral transmission may be higher (0.5% vs 0.3%) [29]. In
Cameroon and Gabon, HCV prevalence increases steeply with
age, far beyond what could be expected from cumulative expo-
sure, representing a cohort effect [30, 31]. Here we show that in
Kinshasa, the city at the center of the emergence of pandemic
HIV-1, the exponential growth rate of HCV from the 1950s on-
ward paralleled that in Egypt, a country in which millions were
infected iatrogenically with the same virus during campaigns
against schistosomiasis [19, 20]. Further, we estimate that HCV
expanded 3 times faster than the population of Kinshasa [5].
Our study provides evidence that at least 2 lineages of HCV
grew exponentially in the Belgian Congo’s capital in the mid-
20th century. Start dates for this growth period were estimated
independently from core and NS5b alignments of subtypes 4k
and 4r by using several models, and all fell between 1947 and
1965, with the great majority of posterior probability being
placed before 1960 (Figure 2). These molecular clock estimates,
consistent with the epidemiological results, which indicate a
higher risk of HCV before 1960, coincide with the period during
which HIV-1 took hold within Kinshasa [4, 5]. We therefore
conclude that a nonnegligible (yet ultimately unquantifiable)
fraction of HIV-1 transmission in Léopoldville during the
time window critical for pandemic establishment occurred
through iatrogenic routes. In the 1960s, high-risk prostitution
appeared in the city [11, 26], fewer diseases required multiple
administration of intravenous drugs, disease control interven-
tions collapsed, and the relative contribution of parenteral
transmission may have consequently declined.
The present findings represent the first empirical evidence for
the hypothesis that iatrogenic transmission played a role in the
emergence of HIV-1 in Kinshasa in the mid-20th century. The
establishment of HIV-1 group M, uniquely among HIV strains,
as a global pandemic undoubtedly resulted frommultiple causal
factors whose relative contributions may never be fully resolved.
However, historical iatrogenic transmission in the hub of Cen-
tral Africa appears to have been one such contributor.
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Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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